Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05132062
Other study ID # IF2740658
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2012
Est. completion date September 1, 2021

Study information

Verified date November 2021
Source Icahn School of Medicine at Mount Sinai
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Consecutive patients having percutaneous coronary intervention (PCI) over a period of 9 years at a large tertiary care center with available creatinine measurements both before and within 48 hours after the procedure were included; patients on chronic dialysis were excluded. Patients treated between 2012 and 2017 comprised the derivation cohort (n=14,616) and those treated from 2018 to 2020 formed the validation cohort (n=5,606). The primary endpoint is contrast-associated acute kidney injury (CA-AKI, defined per Acute Kidney Injury Network [AKIN]). In addition, independent predictors of CA-AKI will be derived from multivariate logistic regression analysis. Model 1 will include only preprocedural variables, while Model 2 will also include procedural variables. A weighted integer score based on the effect estimate of each independent variable will be used to calculate the final risk score for each patient. Impact on 1-year mortality will be also evaluated.


Description:

Consecutive patients who underwent PCI at a tertiary hospital (Mount Sinai Hospital, New York, NY, USA) between 2012 and 2020 with documented serum creatinine both pre- procedure and within 48 hours after PCI were identified from our existing prospectively populated database. Only patients who expired within 48 hours after PCI and with pre-existing end-stage renal disease requiring dialysis were excluded from the present analysis. CA-AKI was defined according to the Acute Kidney Injury Network as an increase by ≥50% or ≥0.3mg/dl within 48 hours after PCI compared to pre-PCI serum creatinine. Anemia was defined as hemoglobin plasma level ≤13 g/dl for men and ≤12 g/dl for women. Chronic kidney disease (CKD) was defined as an estimated glomerular filtration rate (eGFR) of ≤60 ml/min/1.73 m2, per the Chronic Kidney Disease-Epidemiologic (CKD-EPI) formula. A dedicated data coordinating center performed all data management. Prespecified clinical and laboratory demographic information was obtained from hospital charts that were reviewed by independent research personnel who were unaware of the objectives of the study; accumulated data were then entered prospectively in the database. Patients treated between 2012 and 2017 will comprise the derivation cohort (n=14,616) and those treated from 2018 to 2020 will form the validation cohort (n=5,606). Independent predictors of CA-AKI (defined per Acute Kidney Injury Network) will be derived from multivariate logistic regression analysis. Model 1 will include only preprocedural variables, while Model 2 will also include procedural variables. A weighted integer score based on the effect estimate of each independent variable will be used to calculate the final risk score for each patient. Impact on 1-year mortality of CA-AKI occurrence will be also evaluated with Cox regression analysis. Multivariable Cox regression analysis will be also performed to look for independent association of CA-AKI occurrence with mortality.


Recruitment information / eligibility

Status Completed
Enrollment 14616
Est. completion date September 1, 2021
Est. primary completion date January 2, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - patients undergoing PCI - patients with documented serum creatinine both pre- procedure and within 48 hours after PCI Exclusion Criteria: - patients who expired within 48 hours after PCI - patients with pre-existing end-stage renal disease requiring dialysis

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Percutaneous Coronary Intervention
Percutaneous Coronary Intervention is a catheter based technique widely used to restore coronary vessel patency. It is performed by fluoroscopic guidance and it requires the use of iodinated contrast medium. The use of iodinated contrast media has been historically linked to AKI occurring within days after their administration and typically referred to as CA-AKI. Furthermore, CA-AKI has been associated with long-term impairment of kidney function, need for renal replacement therapy, and subsequent all-cause mortality.

Locations

Country Name City State
United States Icahn School of Medicine at Mount Sinai New York New York

Sponsors (1)

Lead Sponsor Collaborator
Icahn School of Medicine at Mount Sinai

Country where clinical trial is conducted

United States, 

References & Publications (3)

McDonald JS, McDonald RJ, Williamson EE, Kallmes DF, Kashani K. Post-contrast acute kidney injury in intensive care unit patients: a propensity score-adjusted study. Intensive Care Med. 2017 Jun;43(6):774-784. doi: 10.1007/s00134-017-4699-y. Epub 2017 Feb 17. Erratum in: Intensive Care Med. 2017 Jun;43(6):956. — View Citation

Mettler FA Jr, Mahesh M, Bhargavan-Chatfield M, Chambers CE, Elee JG, Frush DP, Miller DL, Royal HD, Milano MT, Spelic DC, Ansari AJ, Bolch WE, Guebert GM, Sherrier RH, Smith JM, Vetter RJ. Patient Exposure from Radiologic and Nuclear Medicine Procedures in the United States: Procedure Volume and Effective Dose for the Period 2006-2016. Radiology. 2020 May;295(2):418-427. doi: 10.1148/radiol.2020192256. Epub 2020 Mar 17. — View Citation

Seeliger E, Sendeski M, Rihal CS, Persson PB. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J. 2012 Aug;33(16):2007-15. doi: 10.1093/eurheartj/ehr494. Epub 2012 Jan 19. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of patients developing Contrast-Associated Acute Kidney Injury Contrast-Associated Acute Kidney Injury was defined according to the AKIN as an increase by =50% or =0.3mg/dl within 48 hours after PCI compared to pre-PCI serum creatinine 48 hours after PCI
Secondary Rate of all-cause death Death from all-cause 1 year after PCI
See also
  Status Clinical Trial Phase
Terminated NCT04877847 - Multi-Center Trial Utilizing Low Frequency Ultrasound in the Prevention of Post-Contrast Acute Kidney Injury N/A
Recruiting NCT02088502 - Theophylline, N-acetylcysteine, and Theophylline Plus N-acetylcysteine in Preventing Contrast-induced Nephropathy Phase 2/Phase 3
Completed NCT03329443 - The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography Phase 2
Recruiting NCT04864847 - Clinical Validation of the RENISCHEM L-FABP POC Assay
Completed NCT03627130 - The Use of Inorganic Nitrate for the Prevention of Contrast-induced Nephropathy Phase 2
Active, not recruiting NCT03736018 - Randomised Controlled Trial to Assess Whether Computed Tomography Cardiac Angiography Can Improve Invasive Coronary Angiography in Bypass Surgery Patients N/A
Withdrawn NCT04598516 - Maastricht Investigation of Renal Function in Absence of- and Post- Contrast in Patients With eGFR LEss Than 30
Withdrawn NCT04603261 - Time to Excretion of Contrast, a Maastricht Prospective Observational Study
Recruiting NCT03755700 - Vitamin E and N-acetylcysteine for Preventing Contrast-Induced Acute Kidney Injury After Coronary Artery Catheterization Phase 3
Active, not recruiting NCT04606056 - Risk of Acute Kidney Injury After Intravenous Contrast Computed Tomography Scans
Terminated NCT02440646 - Natural History of Coronary Atherosclerosis in Real-World Stable Chest Pain Patients Underwent Computed Tomography Angiography in Comparison With Invasive Multimodality Imaging
Completed NCT00175227 - Prevention of Contrast-Induced Nephropathy N/A
Completed NCT04014153 - CI-AKI in Patients With Stable CAD and Comorbidities. Are we Doing Better?
Withdrawn NCT04597892 - Efficacy of Point-Of-Care Creatinine Assays in Patients With eGFR <30 Receiving Intravascular Contrast
Completed NCT03305874 - Automated Prediction and Prevention of Contrast Induced Nephropathy After Cardiac Catheterization
Not yet recruiting NCT01871792 - Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction Phase 4
Recruiting NCT05271448 - Continuing or Discontinuing ACE/ARBs in Patients With Chronic Kidney Disease Undergoing Coronary Angiography N/A
Withdrawn NCT03806725 - Safety of Iodinated Contrast in Liver Transplant Candidates With Decreased Renal Function Undergoing Coronary CT Angiography
Completed NCT04163250 - Use of Urinary Cell-Cycle Arrest Biomarkers in Contrast-Associated Nephropathy After Coronary Angiography
Completed NCT04225013 - Early Diagnosis as Strategy in Reducing the Incidence of Contrast-induced Nephropathy